Nitay Ad-El

Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-024-02204-4, published online 23 April 2024. In the version of this article initially published, there was a copy / paste error in the Source Data for Fig. 2g. The figure has been updated, while in the Fig. 2g legend, now reading “Data are fitted in one phase decay curve: 79 bp dsRNA, n = 133,” 133 originally read “138.” The figure, legend and Source Data are now amended in the HTML and PDF versions of the article.

Abstract Ionizable Lipid Nanoparticles (LNPs) are an FDA-approved non-viral RNA delivery system, though their use for brain therapy is restricted by the blood-brain barrier (BBB). Focused ultrasound combined with microbubbles can disrupt the BBB, but delivering large particles requires balancing increased peak negative pressures while maintaining microvascular integrity.

Abstract Efforts to advance RNA aptamers as a new therapeutic modality have been limited by their susceptibility to degradation and immunogenicity. In a previous study, we demonstrated synthesized short double-stranded region-containing circular RNAs (ds-cRNAs) with minimal immunogenicity targeted to dsRNA-activated protein kinase R (PKR). Here we test the therapeutic potential of ds-cRNAs in a mouse model of imiquimod-induced psoriasis.